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Abstract
Background: Schistosomiasis is one of the world’s major public health problems. Besides praziquantel (PZQ), there
is currently no other effective treatment against schistosomiasis. The development of new antischistosomal agents
to curb the emergence of PZQ resistance should be a high priority. Oxadiazole-2-oxides have been identified as
potential antischistosomal reagents, with thioredoxin glutathione reductase (TGR) being one of their molecular
targets.
Methods: To develop novel treatment reagents against Schistosoma japonicum, 30 novel oxadiazole-2-oxides were
synthesised and their antischistosomal activities on juvenile and adult S. japonicum were evaluated in vitro and
in vivo. Their inhibitory activities against S. japonicum thioredoxin glutathione reductase (SjTGR) were also analysed.
Results: Most of the oxadiazole-2-oxides showed good juvenile and adult S. japonica killing activities in vitro.
However, the antischistosomal effects of these compounds were not positively correlated with either their
inhibition of SjTGR, or with nitric oxide (NO) release. Compounds 4a, 4b, 7c, 13, 16 and 20 resulted in 87.7 %,
83.1 %, 87.1 %, 84.6 %, 90.8 % and 69.5 %, respectively, mortality in the adult worms, when used to treat infected
mice at schistosomula stage. These mortality rates were similar to or higher than that of artemisinin. Furthermore,
compounds 4a and 16 resulted in 66.7 % and 69.4 % reductions in the worm burdens, respectively, when infected
mice were treated at the adult worm stage. These treatment effects were similar to PZQ. No differences in activity of
the oxadiazole-2-oxides against female and male adult worms were observed. The toxicity of the oxadiazole-2-oxides
on mammalian cells appeared to be similar to, or less than, that of PZQ.
Conclusions: The antischistosomal activity of the oxadiazole-2-oxides does not depend on NO production or the
inhibition of SjTGR activity. There may be other functional targets of the oxadiazole-2-oxides in S. japonicum. Several of
the novel oxadiazole-2-oxides synthesised in this study could be used to develop novel antischistosomal drugs and
explore potential molecular targets.
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Background
Schistosomiasis is one of the most prevalent parasitic
diseases. It has been estimated that 779 million people
are at risk of infection worldwide [1]. The infection is
caused by trematodes of the genus Schistosoma, among
which Schistosoma mansoni, S. haematobium, S. japoni-
cum, S. mekongi and S. intercalatum represent the most
important pathogenic species for human beings. De-
pending on the species, the worms (schistosomes) per-
sist in the liver and hepatic portal system or the urinary
tract system of humans. Mature schistosomes lay eggs
within their host, which often get trapped in the host’s
tissues, resulting in inflammatory and obstructive dis-
eases of the affected organs [2]. In China, the disease
caused by S. japonica is a major public health concern,
with more than 280 thousand people infected [3]. To
cure subtle morbidity and prevent the development of
severe chronic stage hepatosplenomegaly, praziquantel
(PZQ) is the only choice of chemotherapy. The drug has
been widely used for more than three decades and is
therefore susceptible to the emergence of praziquantel-
resistant schistosomes [4]. In addition, the mechanism
by which PZQ works is still undefined [5].
A number of recent studies have attempted to modify
PZQ [6–12], explore new chemical entities from natural
products [13] and identify additional drug targets for the
chemotherapy of schistosomiasis [14–18]. Oxadiazole-2-
oxides were identified as new drug leads against S. man-
soni, while thioredoxin glutathione reductase (TGR) was
found to be a potential molecular target of the oxadiazole-
2-oxides [15, 16]. Previously, we have shown that S. japo-
nicum TGR (SjTGR) plays an essential role in maintaining
the redox balance in S. japonicum and confirmed SjTGR
as a potential target for the development of new drugs
against schistosomiasis [18].
To our knowledge, few data have been reported for
oxadiazole-2-oxides against S. japonicum [16]. We de-
signed and synthesised novel oxadiazole-2-oxides to target
SjTGR. The results show that some novel oxadiazole-2-
oxides had a good killing activity against S. japonicum, but
did not inhibit the activity of SjTGR, implying that




5,5’-Dithiobis-(2-nitrobenzoic acid) (DTNB) and β-
nicotinamide adenine dinucleotide 2’-phosphate reduced
tetrasodium salt (NADPH) were purchased from Roche
(Basel, Switzerland). RPMI 1640 and fetal bovine serum
were from Gibco (Invitrogen Corporation, Carlsbad,
USA). 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetra-
zolium bromide (MTT), dimethyl sulfoxide (DMSO) and
PZQ were sourced from Sigma-Aldrich Inc. (Saint Louis,
USA). The Nitric Oxide Assay Kit and 2-(4-carboxy-
phenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide
(carboxy-PTIO) came from Beyotime Biotechnology
Corporation (Shanghai, China). Ethylenediaminetetra-
acetic acid (EDTA) and 2-[4-(2-hydroxyethyl)-1-piper-
azinyl]ethanesulfonic acid (HEPES) were purchased
from Sangon Biotech Co. Ltd. (Shanghai, China), and
artemisinin (AS) was purchased from Zelang Medical
Technology Co. Ltd. (Nanjing, China).
Parasites and experimental animals
Infected Oncomelania hupensis, provided by the Depart-
ment of Snail Biology, Jiangsu Institute of Parasitic Dis-
eases, were incubated at 25–28 °C, under illumination,
for 2 h to hatch S. japonicum cercariae. The cercariae
were collected from the water surface with clean cover
glass and placed into a centrifuge tube using pre cooled
RPMI 1640. Centrifugation was performed for 1 min at
1500 rpm, and then the steps above were repeated. After
centrifugation, the supernatant solution was removed.
The cercariae at the bottom were washed twice and re-
suspended with RPMI 1640. Approximately 20–30 cer-
cariae (1 mL of the resuspension medium) were added
to one well in a 24-well culture plate. They were incu-
bated overnight at 37 °C with 5 % CO2. The survival
rates and number of tails shed were observed under an
inverted microscope. Cercariae that had shed their tails
were used as juvenile S. japonicum [19, 20].
ICR mice (20–22 g), were obtained from the Shanghai
Sub-Center of Experimental Animals, Chinese Academy
of Sciences. They were maintained at the Department of
Experimental Animals, Jiangsu Institute of Parasitic Dis-
eases. To infect each mouse, its abdominal skin was ex-
posed to 50 S. japonica cercariae. All of the mice were
executed to collect S. japonica adult worms, through
portal vein perfusion, 35 days post-infection [21]. The
adult S. japonica collected were washed with RPMI 1640
medium and then kept in RPMI 1640 medium (pH 7.5)
with HEPES 20 mM, penicillin (100 IU/mL), strepto-
mycin (100 mg/mL) and 10 % fetal bovine serum [22].
Then, two pairs of adult worms were transferred into
each well of a 24-well culture plate, with 2 mL of the
same medium. The worms were cultured at 37 °C in a
humid atmosphere with 5 % CO2.
Synthesis of oxadiazole-2-oxide derivatives
Compounds 4a–4c, 7a–7c and 8 were prepared using
a protocol similar to that reported by the Maloney
group (Scheme 1) [15]. To make compounds 9–21
(Scheme 2), compound 8 was coupled with various
bromides in the presence of Cs2CO3, with yields of
40–60 %. For compound 22, compound 7b was treated
with N-bromosuccinimide (NBS) and azodiisobutyro-
nitrile (AIBN) in CCl4, obtaining a yield of 54 %. Then,
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compound 22 was coupled with various aromatic alco-
hols, using Cs2CO3 as the base in DMF, to give com-
pounds 23–30, the yields of which varied from 25 to
45 %. The procedures for the preparation of com-
pounds are detailed in Additional file 1.
Oxadiazole-2-oxides inhibition of recombinant SjTGR
The purified recombinant SjTGR proteins were pro-
duced according to the method described by Song et al.
[18]. The inhibition of TrxR activity by the recombinant
SjTGR was performed as reported by Rai et al. [15].
Briefly, 50 nM SjTGR and 1 mM NADPH were incu-
bated with different concentrations of oxadiazole-2-
oxides (2, 4, 6, 10, 20 μM) for 15 min at room
temperature. Then, potassium phosphate buffer (pH 7.4)
containing 10 mM EDTA, 100 μM NADPH, and 3 mM
DTNB was added to start the reaction. The increase of
absorbance at 412 nm was monitored during the first
2 min. All assays were done in triplicate. Assays with no
inhibition were performed as the control treatment. The
50 % inhibitory concentration (IC50) values of the
oxadiazole-2-oxides were calculated by curve fitting,
using SPSS 13.0 statistical software.
Detection of nitric oxide (NO) release
The release of nitric oxide (NO) was measured as previ-
ously reported [16]. Briefly, 15 nM SjTGR, with or with-
out 100 μM NADPH or 5 mM cysteine, was incubated
at room temperature with 10 μM of the oxadiazole-2-
oxides for 50 min. The NO release was detected accord-
ing to the instructions of the Nitric Oxide Assay Kit,
with the absorbance being measured at 540 nm. The
NO release of sodium nitrite, as a standard substance,
was also measured. The values of NO release were cal-
culated on the basis of the regression line plotted for the
NO release from sodium nitrite. Each reaction was done
in triplicate and the data presented are the average of
three independent experiments.
Healthy S. japonica adult worms were collected as de-
scribed above and homogenized in 0.1 M potassium
phosphate (pH 7.4). The homogenates were centri-
fuged at 20,000 g for 1 h at 4 °C and the supernatants
were assayed for NO release. In addition, the worm
homogenates (100 μg) were incubated with 10 μM
oxadiazole-2-oxides for 50 min at room temperature
and the production of NO was detected as above.
Each reaction was done in triplicate.
Cytotoxicity assay of oxadiazole-2-oxides on Hela cells
Cytotoxicity assays were performed using Hela cells.
Cells in the exponential growth phase were collected by
centrifugation and a concentration of 4–5 × 104/mL was
created. 100 μL of the cell suspension was added to each
well of a 96-well plate and cultured overnight at 37 °C in
a humid atmosphere with 5 % CO2. Oxadiazole-2-oxides
(at 10, 20, 40, 80 and 160 μM) were added. Each concen-
tration was assayed in triplicate, and control wells (no
cells and no drugs) were assayed at the same time. The
Scheme 1 Synthesis of compounds 4a–4c and 7a–7c. Reagents and conditions: (a) EtOH, H2SO4, reflux, overnight; (b) DIBAL-H, DCM, N2, −70 °C
to rt, 12 h, 90–95 %; (c) NaNO2, HOAc, H2O, 0 °C to rt, 25–32 %; (d) MnO2, DCM, water–ice to rt, 4 h, 92 %; (e) NH4OH-HCl, pyridine, EtOH, 90 °C,
3 h, 49 %; (f) SOCl2, DMF, N2, 30 °C, 12 h, 70–75 %
Scheme 2 Synthesis of compounds 8–21. Reagents and conditions: (g) DL-methionine, methanesulfonic acid, N2, 70 °C, 2 h, 53 %; (h) bromides,
Cs2CO3, DMF, 30–60 °C, 40–60 %
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“no cell” control wells only contained RPMI 1640
medium, MTT, DMSO, and oxadiazole-2-oxides. The
“no drug” control wells contained the Hela cells, RPMI
1640 medium, MTT and DMSO. The cells were cultured
for 48 h at 37 °C in a humid atmosphere with 5 % CO2.
Then, 20 μL of 5 mg/mL MTT was added to each well
and the culture conditions were maintained for 4 h.
After this point, the medium was removed and 150 μL
DMSO was added into each well to dissolve any crystal-
lisation. The value of absorbance at 570 nm of each well
was measured (at 570 nm) with a microplate reader to
assess the toxic effect of the oxadiazole-2-oxides on the
vertebrate cells.
Toxicity of oxadiazole-2-oxides on juvenile and adult S.
japonica in vitro
Oxadiazole-2-oxides (10 μmol) were dissolved in 1 mL
DMSO to prepare stock solutions, which were kept cold
and in the dark. Working solutions were prepared prior
to use at the appropriate dilutions, using RPMI 1640
medium.
20–30 juvenile worms were transferred into each well
of a 24-well culture plate, containing 2 mL RPMI 1640
medium, 20 mM HEPES, 100 IU/mL penicillin, 100 mg/
mL streptomycin and 10 % fetal bovine serum. Then,
oxadiazole-2-oxides (2, 5, 10, and 50 μM), diluted with
the RPMI 1640 medium, were added to their allocated
wells. The worms in the negative control wells were
treated with equal volumes of RPMI 1640 or DMSO and
worms treated with AS were observed as positive con-
trols. The juvenile worms’ survival rates were observed
under an inverted phase contrast microscope (Leica,
Wetzlar, Germany) at 24, 48 and 72 h. Parasite death
was defined as an unclear internal structure of the ju-
venile worms, with incomplete tegument and contents
overflowing radially, or unclear internal structure with
complete tegument, but having no motor activity during
1 min of continuous observation [23]. All assays were re-
peated three times.
Adult worms were cultured in a 24-well culture plate
for 30–60 min at 37 °C, in a humid atmosphere with
5 % CO2. Then, oxadiazole-2-oxides at different concen-
trations (10, 25, 50, 100 μM) were added. Equal volumes
of RPMI 1640 or DMSO were applied as negative con-
trols, while PZQ was applied as a positive control. The
adult worm mobility and parasite survival rates were
monitored using an inverted phase contrast microscope,
at 24, 48 and 72 h. Parasite death was defined as there
being no motor activity during 2 min of continuous ob-
servation, and morphological and tegumental alterations
[24]. All assays were repeated three times.
To assess the importance of NO production, the po-
tassium salt of carboxy-PTIO, a NO scavenger, was dis-
solved in water and 100 mM was incubated with freshly
perfused adult S. japonica in the presence or absence of
10 mM oxadiazole-2-oxides. The worms’ mobility, tegu-
mental alterations and parasite survival were monitored
using an inverted microscope. The experiment was done
in triplicate.
Oxadiazole-2-oxides treating S. japonica in vivo
The abdominal skin of each mouse (ICR, female, 22–
24 g) was exposed to 20 S. japonica cercariae (as de-
scribed above). The mice were intraperitoneally injected
with 10 mg/kg oxadiazole-2-oxides daily for 5 days, be-
ginning either 7 or 35 days post-infection. Control mice
were treated with 10 mg/kg of the carrier medium. All
mice were sacrificed 42 days post-infection. The worm
burden of each mouse was confirmed by counting the
number of worms observed from a portal vein perfusion.
The mouse livers were digested overnight with 5 % po-
tassium hydroxyl solution at 37 °C and the eggs in the
liver tissue were counted under an inverted phase con-
trast microscope. The worm and egg reduction rates
were calculated using the following formulas [18]:
Worm reduction rate %ð Þ ¼ ðmean number of adult worms
per mouse in control group−
mean number of adult worms
per mouse in experimental groupÞ
= mean number of adult worms per
mouse in control group:
Egg reduction rate %ð Þ ¼ ðmean number of eggs per mouse in
control group−mean number of eggs
per mouse in experimental groupÞ
= mean number of eggs per mouse in
control group:
Statistical analysis
All data are given as the mean ± standard deviation (SD).
The worm and egg burden numbers after treatment with
oxadiazole-2-oxides were statistically compared with the
control, AS or PZQ groups using two-tailed Student’s t-
tests. Differences in NO release from the oxadiazole-2-
oxides compared with control were similarly assessed. Cell
survival rates after exposure to oxadiazole-2-oxides and
PZQ, and worm survival rates after exposure to
oxadiazole-2-oxides, with or without carboxy-PTIO, were
determined using chi-square tests. SPSS 13.0 was used for
the statistical analyses. Differences between mean values
were considered to be significant at the level of 5 %.
Ethical approval
Ethical approval for the work performed was obtained
from the Institutional Review Board (IRB00004221) of
Jiangsu Institute of Parasitic Diseases, Wuxi, China (Per-
mit Number: JIPDAERP20131120). All animals were
housed in facilities and provided food and water
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conventionally. The infection, intraperitoneal injections
and sacrifices (by carbon dioxide asphyxiation) were car-
ried out according to recommendations in the Guide-
lines for the Care and Use of Laboratory Animals of the
Ministry of Science and Technology of People’s Republic
of China ([2006]398). Suffering was minimised in ac-
cordance with the guidelines.
Results
Syntheses of oxadiazole-2-oxides and their inhibitory
activities against SjTGR
Thirty oxadiazole-2-oxides were designed and synthe-
sised following Schemes 1, 2, 3. The structures of these
oxadiazole-2-oxides are detailed in Table 1. The recom-
binant SjTGR was incubated with each oxadiazole-2-
oxide, and their respective inhibition on the TrxR activ-
ity of SjTGR was observed. The results showed that
compounds 4a, 4b, 4c, 7a, 7b, 7c, 8, 11, 12, 13, 14, 16,
20 and 22 inhibited the activity of SjTGR (Fig. 1 and
Table 1), with IC50 values between 0.5 and 37.4 μM.
Compounds 9, 10, 15, 17, 18, 19, 21, 23, 24, 25, 26, 27,
28 and 29 did not inhibit the activity of SjTGR
(Table 1).
NO production of oxadiazole-2-oxides in vitro
When the oxadiazole-2-oxides were incubated with cyst-
eine at room temperature, compounds 7c, 13, 16, 20,
and 22 released 9.0 ± 0.5, 8.6 ± 0.4, 8.3 ± 0.0, 8.8 ± 0.7,
and 9.0 ± 0.1 μM NO, respectively. The PBS and DMSO
control wells produced 3.6 ± 0.4 and 3.2 ± 0.5 μM NO,
respectively (Fig. 2). The difference in NO production
between the above five compounds and DMSO was sig-
nificant (P < 0.05). The other oxadiazole-2-oxides pro-
duced similar NO levels to the PBS and DMSO control
wells (Fig. 2; P > 0.05). Incubation of the oxadiazole-2-
oxides with SjTGR +NADPH, SjTGR alone or worm
homogenate supernatant, also released similar NO to
the PBS and DMSO controls (P > 0.05; Additional file 2:
Table S1).
Cytotoxicity of oxadiazole-2-oxides on Hela cells
The cytotoxicity assessment of the oxadiazole-2-oxides
on the Hela cells was observed using the MTT method.
The viability of the Hela cells immersed in 80 μM of
PZQ for 72 h was 76 %, while those in 80 μM of com-
pounds 4a, 4b, 7c, 13, 16, 20 after 72 h were 91 %,
96 %, 66 %, 80 %, 89 % and 87 % viable, respectively. Ex-
cept for compound 7c, the toxicity of compounds 13,
4a, 4b, 20, and 16 to the Hela cells was similar to, or
less than that of PZQ. The differences in toxicity were
not significant, between the oxadiazole-2-oxides and
PZQ (P > 0.05).
Toxicity of oxadiazole-2-oxides to cultured juvenile and
adult S. japonica
The survival of juvenile and adult S. japonica, cultured
in a medium, containing different concentrations of
oxadiazole-2-oxides showed that, compared to AS – AS
at 50 μM resulted in the death of 51.3 ± 5.1 % juvenile
worms after 24 h – compounds 4b, 7c, 9, 22 and 23 at
50 μM increased mortality, to more than 70.0 % after
24 h. In contrast, compounds 4c, 7a, 8, 12, 13, 16, 17,
21 and 28 (at 50 μM) did not affect the juvenile worms,
with less than 30.0 % mortality after 24 h. Compared to
PZQ, which, at 25 μM resulted in the death of 25.0 ±
7.8 % adult worms after 24 h, compounds 7a, 7b, 7c, 12,
14, 18, 19, 22, 23, 24, 26 and 28 at 25 μM increased
mortality, to more than 75.0 %. Compounds 17 and 29
did not cause death in the adult worms after 24 h, even
at the maximum concentration tested (100 μM). Inter-
estingly, we found that compounds 4a, 7c, 13, 16 and
20 displayed killing activities to both the juvenile and
adult worms of S. japonica. At concentrations of 50 μM,
compounds 7c, 13 and 16 resulted in 100.0 ± 0.0 % mor-
tality of adult worms within 24 h, and 100.0 ± 0.0 %,
41.0 ± 6.3 % and 72.1 ± 3.7 % mortality of juvenile worms
after 72 h, respectively. 100 μM of compounds 4a, 20
caused 100.0 ± 0.0 % of the adult worms to die, and 90.0
± 2.8 % and 67.6 ± 4.5 % of the juvenile worms died in
72 h, respectively. 100 μM of compound 4b resulted in
57.1 ± 2.1 % adult worm death at 24 h, 100.0 ± 0.0 %
adult worm mortality after 48 h, and 100.0 ± 0.0 % ju-
venile mortality at 72 h. The killing activities against the
juvenile and adult worms of these 7 compounds in-
creased with concentration and time (Additional file 3:
Tables S2 and Additional file 4: Table S3, Fig. 3a, b, c, d).
Scheme 3 Synthesis of compounds 22–30. Reagents and conditions: (b) NBS, AIBN, CCl4, 80 °C, overnight, 54 %; (c) aromatic alcohols, or Cs2CO3,
DMF, 30–60 °C, 25–45 %
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There was no statistically significant difference in mor-
tality due to the sex of the worms, among the seven
compounds (Fig. 3e). When a NO scavenger (carboxy-
PTIO) was added to the culture of adult worms in vitro,
with compounds 7c and 16, there were no differences in
the killing activities of the compounds (with or without
carboxy-PTIO; P > 0.05) (Fig. 4).
The treatment effect of oxadiazole-2-oxides in vivo
The results of treating the mice with the oxadiazole-2-
oxides in vivo showed that compounds 4a, 4b, 7c, 13,
16 and 20 caused 87.7 %, 83.1 %, 87.1 %, 84.6 %, 90.8 %
and 69.5 % mortality in the adult worms, respectively;
and the eggs were reduced by 47.0 %, 0 %, 52.0 %,
52.6 %, 49.5 % and 3.3 %, respectively (when the mice
were treated at the juvenile worm stage). There was a
significant rise in the adult worm reduction rate of com-
pound 16, compared to the AS group (78.5 % in worm
burdens, P < 0.05) (Table 2). Compounds 4a and 16 re-
sulted in 66.7 % and 69.4 % reductions in the worms, re-
spectively, and 3.8 % and 20.0 % reduction in the eggs,
respectively (when the mice were treated at the adult
worm stage). The treatment effect of compounds 4a and
16 were similar to that of PZQ (worm reduction rate
was 72.3 %; P > 0.05). The other novel oxadiazole-2-
oxides tested appeared to not affect the adult worms
(Table 3).
Discussion
For almost three decades, PZQ has been the only drug
recommended by the World Health Organization to
treat and control schistosomiasis, through mass drug ad-
ministration (MDA) programs [25]. No vaccine has ever
been developed [25]. PZQ does not guard against reinfec-
tion and is not effective against juvenile schistosomes. Fur-
thermore, schistosome phenotypes are emerging that are
resistant to PZQ chemotherapy, and PZQ has a limited ef-
fect on developed liver and spleen lesions [4, 26]. Al-
though these issues have not led to treatment failures or
the necessity to change control measures to date, it is im-
perative to develop new antischisosomal agents in antici-
pation of the potential threat.
Oxadiazole-2-oxides have been identified to inhibit the
activity of TGR and kill S. mansoni worms during the in
vivo treatment of schistosome-infected mice, which led
to more than 90 % reduction in the worm burdens [15,
16]. However, there has been little attention on the effect
of the oxadiazole-2-oxides against S. japonica, a hel-
minth endemic to Asia. We designed and synthesised 30
oxadiazole-2-oxides, on the basis of Schemes 1, 2, 3, and
studied their killing activities against juvenile and adult
S. japonica. The mechanisms of action of the
oxadiazole-2-oxides were also explored.
Table 1 Structures of the oxadiazole-2-oxides and their inhibitory
activities against SjTGR
a SjTGR enzymatic assay
b No activity
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The in vitro antischistosomal activity on juvenile and
adult S. japonica, as well as their inhibitory activity
against SjTGR (assessed using our previously reported
protocol [18]) showed (Table 1 and Additional file 3: Ta-
bles S2 and Additional file 4: Table S3) that compounds
7a–c and 8 had the same structures as those described
in the work with S. mansoni [15]. These compounds had
good worm killing activity, resulting in 100.0 ± 0.0 %,
83.3 ± 4.7 %, 70.0 ± 7.1 %, and 71.4 ± 0.9 % mortality in
the adult worms after 72 h, at concentrations of 10 μM,
respectively; these mortality levels are similar to the data
(100.0 %, 70.0 %, 100.0 %, and 100.0 %, respectively) ob-
tained using S. mansoni [15]. These data show that the
oxadiazole-2-oxides may have the same pharmacology in
both schistosome species.
Comparing compounds 4a–4c and 7a–7c, the cyano
group in compound 7c replaced the hydroxyl group in
compound 4c, and at 100 μM, compound 4c caused
57.1 ± 2.3 % mortality while compound 7c caused 100.0
± 0.0 % mortality in the adult worms. When the hy-
droxyl group in compound 4a was changed into cyano
group of compound 7a, the activity against SjTGR
slightly weakened (the IC50 values were 2.7 μM and
12.2 μM, respectively), but the worm killing activity of
7a was markedly enhanced. In contrast, compound 4b
had both better activity against SjTGR and better worm
killing activity, than 7b. In compounds 9–11 the number
of CH2 groups between the O atom and ester group in-
creased, the corresponding SjTGR inhibitory effects
increased, but the worm killing activity did not. Interest-
ingly, compound 9, which had no SjTGR inhibitory
activity, caused the best worm mortality of the three com-
pounds. Among compounds 12–16, compounds 12, 13
and 14 caused moderate SjTGR inhibition and had good
worm killing activities. Compound 15 did not inhibit
SjTGR and exhibited similar worm killing activity at
10 μM to compounds 12, 13 and 14. Changing the C–C
single bond (compound 15) into a double bond (C =C;
compound 16), inhibited SjTGR at sub-micromolar con-
centrations (IC50 = 0.54 μM), but there was no change in
activity against the parasite.
As for compounds 17–21, compound 18, with an iso-
pentyloxy group, did not inhibit SjTGR, while com-
pound 20 with a prop-2-yn-1-yloxy group inhibited
SjTGR at low micromolar concentrations; these two
compounds both killed 100.0 ± 0.0 % of worms in 72 h,
Fig. 1 Inhibition of recombinant SjTGR by oxadiazole-2-oxides. 50 nM SjTGR and 1 mM NADPH were incubated with different concentrations of
oxadiazole-2-oxides (2, 4, 6, 10, 20 μM) for 15 min at room temperature. Then, potassium phosphate buffer (pH 7.4) containing 10 mM EDTA,
100 μM NADPH, 3 mM DTNB was added to start the reaction. The increase in absorbance at 412 nm was monitored during the first 2 min. All
assays were done in triplicate. Results shown are the mean ± SD (n = 3)
Fig. 2 Nitrogen orxide (NO) release from oxadiazole-2-oxides incubated
in vitro. 15 nM SjTGR, 100 μM NADPH and 5 mM cysteine were
incubated with 10 μM oxadiazole-2-oxides for 50 min at room
temperature. The nitric oxide (NO) released was detected according to
the NO Assay Kit (Beyotime Biotechnology Corporation). The NO
release levels were calculated based on the regression line of sodium
nitrite (standard). Each reaction was done in triplicate. Results shown
are the mean ± SD (n = 3)
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at concentrations of 25 μM. The symmetrical compound
21 did not inhibit SjTGR and exhibited slightly poorer
worm killing activity than compound 13. Interestingly,
compound 19, with a benzyloxy group, was the best at
killing worms among all the compounds assessed. How-
ever, with a carbonyl group inserted between the phenyl
group and carbon atom, compound 17 was poor at kill-
ing worms.
Among compounds 22–29, those with bulkier aro-
matic groups (compounds 27, 28 and 29) caused low
mortality rates, compared with compound 19, which
had a smaller phenyl group. In addition, compounds
without substitution on the phenyl group (compounds
19 and 23) were better at killing the worms than those
with substitution (compounds 24, 25 and 26). Except for
compounds 25 and 29, the other oxadiazole-2-oxides
caused higher worm mortality rates than PZQ. Com-
pound 22 moderately inhibited SjTGR, and had a good
worm killing activity; this indicates the worm killing ac-
tivities of the oxadiazole-2-oxides were not directly cor-
related to their SjTGR inhibitory activities.
The results of the mice experiments showed large and
highly significant reductions in worm burdens by treat-
ing the mice at juvenile worm stage with compounds 4a,
4b, 7c, 13 and 16, compared to AS. The treatment ef-
fects of compounds 4a and 16 were almost the same as
Fig. 3 Effects of oxadiazole-2-oxides on mortality of juvenile and adult S. japonica in vitro. Oxadiazole-2-oxides were applied at different concentrations
and mortality was measured in the juvenile worms after 72 h (a) and adult worms after 24 h (b). In c, the mortality of juvenile S. japonica caused by
the oxadiazole-2-oxides (50 μM) at different exposure times is shown. In d the mortality of adult S. japonica caused by the oxadiazole-2-oxides (10 μM)
at different exposure times is shown. In e, the mortality of male and female adult specimens of S. japonica exposed to 8 μM of oxadiazole-2-oxides
after 120 h is shown
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PZQ, at the adult worm stage. These results generally
agree with Rai et al. [15], who reported that oxadiazole-
2-oxide derivatives nearly cured S. mansoni-infected
mice, with a 90 % reduction in the worm burdens. How-
ever, there was a contradiction between the worm and
egg reduction rates in the PZQ and oxadiazole-2-oxides
treatments for the mice; compounds 4a and 16 seemed
to eliminate the adult parasites essentially to the same
extent as PZQ, but had less effect on the egg burden
than PZQ. The main reason was that the reductions in
the female worms due to treatment with compounds 4a
and 16 were 36.8 % and 44.7 %, which was less than the
reduction in female worms due to PZQ treatment
(60.5 %) (data not shown). This structure activity
relationship (SAR) could have important implications for
further drug development of the oxadiazole-2-oxides
against schistosomiasis.
The oxadiazole-2-oxide core is a class of NO donating
compounds [27]. NO is a free radical and is a well-
studied physiological signaling agent; it is best known
for its ability to relax smooth muscle tissue, resulting in
vasodilatation and increased blood flow at low concen-
trations [28]. However, elevated levels of NO can be
toxic, which can kill normal cells, tumuor cells, bacteria
and parasites [29–31]. Rai et al. [15] proposed that
oxadiazole-2-oxides kill S. mansoni due to the free thiols
of TGR, which can attack the oxadiazole-oxide, affecting
its molecular arrangement and releasing of NO; they
Fig. 4 Activity of oxadiazole-2-oxides against adult S. japonica in vitro, with and without carboxy-PTIO. Carboxy-PTIO was incubated with freshly
perfused adult S. japonica at 100 mM in the presence and absence of 10 mM oxadiazole-2-oxides. The worms’ mobility, tegumental alterations
and survival rates were monitored under an inverted microscope. The experiment was done in triplicate. The percentage of adult worms that
survived are shown (mean ± SD; n = 3)
Table 2 Treatment effects of oxadiazole-2-oxides on juvenile S. japonicum in mice
Groups Mice No. Number of worms
(Mean ± SD)
Worm reduction rate (%) Number of eggs per gram of liver
(Mean ± SD)
Egg reduction rate (%)
Control 7 10.8 ± 0.8 8,032.9 ± 2,192.1
Compound 4a 4 1.3 ± 0.8 (P > 0.05**) 87.7 (P < 0.01*) 4,258.9 ± 1,910.0 (P > 0.05**) 47.0 (P < 0.05*)
Compound 4b 2 1.8 ± 1.5 (P > 0.05**) 83.1 (P < 0.01*) 8,669.2 ± 2,255.8 (P < 0.05**) –
Compound 7c 2 1.4 ± 0.8 (P > 0.05**) 87.1 (P < 0.01*) 3,859.4 ± 3,749.4 (P > 0.05**) 52.0 ( P > 0.05*)
Compound 13 2 1.7 ± 0.7 (P > 0.05**) 84.6 (P < 0.01*) 3,808.9 ± 1,288.9 (P > 0.05**) 52.6 (P < 0.05*)
Compound 16 5 1.0 ± 0.5 (P > 0.05**) 90.8 (P < 0.01*) 4,054.5 ± 1,322.1 (P > 0.05**) 49.5 (P < 0.01*)
Compound 20 6 3.0 ± 0.9 (P < 0.05**) 69.5 (P < 0.01*) 7,767.5 ± 2,676.6 (P < 0.05**) 3.3 (P > 0.05*)
AS 4 2.3 ± 1.0 78.5 (P < 0.01*) 2,932.2 ± 1,149.3 63.5 (P < 0.01*)
*Effect of compound versus control analysed by Student’s t-test; **Effect of compound versus AS analysed by Student’s t-test
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supposed that the concomitant inhibition of TGR activ-
ity would result in the accumulation of reactive oxygen
species and increase oxidative stress. However, our NO
release and scavenger experiment showed that when
compounds 7c, 13, 16, 20 and 22, and furoxan with a
cyano group, were incubated with cysteine, the release
of NO increased. When the cyano group of com-
pounds 4a and 4b were replaced with a hydroxyl
group, no NO release was observed. These results
show that the release of NO was related to the cyano
group. However compounds 21, 23 and 26 had a cyano
group, but did not release NO. Compared with the
structure of compounds 7c, 13, 16, 20 and 22, this
may be related to the hydrogen, which was replaced by
a benzene ring, influencing the spatial structure of the
compounds. Therefore, the release of NO may be rele-
vant to the position of the cyano group in the com-
pound. Compounds 4a, 4b, 7c, 13, 16, 20 and 22
released NO and the values of their activity against
SjTGR were all under 10 μM. Compounds 19, 21 and
26 did not release NO and neither did they inhibit the
SjTGR activity. It appears that the release of NO may
inhibit the activity of SjTGR. However, compounds 4a
and 4b did not release NO, but did strongly inhibit
SjTGR, with IC50 values of 2.7 and 1.7 μM. These
results indicate that oxadiazole-2-oxides have other
mechanisms against SjTGR activity.
In addition, when the oxadiazole-2-oxides were incu-
bated with SjTGR or worm homogenate for 50 min at
room temperature, no NO release was observed. This il-
lustrates that the relationship between SjTGR inhibition
and the release of NO by oxadiazole-2-oxides needs fur-
ther investigation. Even though compounds 23 and 26
did not release NO they had good activity against the
worms in vitro; the NO clear experiment showed that
there was no difference in the killing activity of the
oxiadiazole-2-oxides against the worms in vitro, with
or without carboxy-PTIO. This shows that the effects
of the drugs against the worms were not correlated
with the NO release from the oxiadiazole-2-oxides,
indicating that there are other mechanisms, besides
NO, that led to mortality of the parasites. That is, the
oxadiazole-2-oxides synthesised in this study may
have another target, in addition to SjTGR, through
which they kill S. japonica.
Our study shows that there were no obvious correla-
tions among the activity of oxadiazole-2-oxides against
S. japonicum worms, SjTGR inhibition and the produc-
tion of NO. One reason for this could be as suggested
by Rai et al. [15]; worm death may not occur until the
GSH/GSSG ratio reaches a critical point and the overall
worm redox balance is unrecoverable, making it difficult
to derive correlations between mortality in the worms
and TGR inhibition below a certain level. In addition,
Treger et al. [32] reported that oxadiazole-2-oxides kill
Ancylostoma ceylanicum and proved that their target
was not glutathione reductase. Besides these reasons,
several studies [33–36] have shown that oxadiazole-2-
oxides have many functions, which have been used in
new drug developments against bacteria, fungi, viruses,
worms, tumors, syncopes and immune suppressors.
This indicates that oxadiazole-2-oxides may have a lot
of function targets. Our study has shown that
oxadiazole-2-oxides may have other targets and mech-
anisms, in addition to SjTGR and its inhibition, within
S. japonicum.
Conclusions
In this study, a series of novel oxadiazole-2-oxides
were designed and synthetised. Some of them killed
juvenile and adult S. japonica effectively. The anti-
schistosomal activity of these compounds was related
to their structure, but not positively correlated to the
inhibition of SjTGR or NO release. These oxadiazole-
2-oxides may serve as the leads to develop novel anti-
schistsosomal drugs and explore potential molecular
targets further.
Table 3 Treatment effects of oxadiazole-2-oxides on adult S. japonicum in mice
Groups Mice No. Number of worms
(Mean ± SD)
Worm reduction rate (%) Number of eggs per gram of liver
(Mean ± SD)
Egg reduction rate (%)
Control 7 12.0 ± 2.1 8032.9 ± 2192.1
Compound 4a 4 4.0 ± 2.5 (P > 0.05**) 66.7 (P < 0.01*) 7730.8 ± 1457.8 (P < 0.05**) 3.8 (P > 0.05*)
Compound 4b 4 9.0 ± 3.8 (P < 0.05**) 25.0 (P > 0.05*) 7007.8 ± 2420.2 (P < 0.05**) 12.8 (P > 0.05*)
Compound 7c 6 12.0 ± 3.9 (P < 0.05**) – 7213.0 ± 2658.0 (P < 0.05**) 10.2 (P > 0.05*)
Compound 13 5 8.6 ± 2.4 (P < 0.05**) 28.3 (P < 0.05*) 8201.4 ± 2066.0 (P < 0.05**) –
Compound 16 5 3.7 ± 1.4 (P > 0.05**) 69.4 (P < 0.01*) 6424.1 ± 1193.4 (P < 0.05**) 20.0 (P > 0.05*)
Compound 20 6 4.7 ± 1.1 (P > 0.05**) 61.1 (P < 0.01*) 10094.7 ± 1691.0 (P < 0.05**) –
PZQ 6 3.3 ± 1.7 72.3 (P < 0.01*) 3721.5 ± 1600.6 53.7 (P < 0.01*)
* Effect of compound versus control analysed by Student’s t-test; **Effect of compound versus PZQ analysed by Student’s t-test
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